News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management

All Releases

05 December 2007 CSL Behring study in animal models shows feasibility of developing a half-life extended recombinant FVIIa that retains biologic activity

CSL Behring today announced the results of a pre-clinical study that show for the first time it is feasible to genetically fuse Factor VIIa (FVIIa) to human albumin, prolonging the half-life of this therapeutic protein while retaining its biologic activity. In the study, which was presented at the American Society of Hematology 49th Annual Meeting and Exposition, the half-life of recombinant VIIa–albumin fusion protein (rVIIa-FP) was shown to be extended 6-to-9 fold compared to wild type rFVIIa. Additionally, rVIIa-FP demonstrated a biologic activity comparable to wild type rFVIIa.

> Read More
26 November 2007 CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema

CSL Behring announced today that it has reached the primary endpoint of a Phase III clinical trial of human pasteurized C1-inhibitor (C1-INH) concentrate to treat patients with hereditary angioedema (HAE), a rare genetic disorder that can lead to painful and sometimes life-threatening attacks of edema (swelling) of the face, airway, abdomen, and extremities.

> Read More
14 November 2007 Study Shows Need to Test Greater Number of COPD and Asthma Patients for Underdiagnosed Pulmonary Disease

A new study finds that a higher than expected number of COPD and severe asthma patients had abnormal low levels of alpha-1 antitrypsin (AAT), suggesting that need for broader criteria for AAT deficiency testing. AAT deficiency, also known as Alpha-1, is a widely undiagnosed hereditary disorder that is usually fatal in its severe form.

> Read More
09 November 2007 L-Proline Stabilizer Used in the Intravenous Immunoglobulin Product Privigen® Shows No Neurological Side Effects Compared with Currently Used Stabilizers

CSL Behring announced new data today that demonstrates that L-proline causes no neurological effects, including convulsive behaviour and spatial learning and memory, even at high doses, when compared with glycine, which is used in many current intravenous immunoglobulin (IVIg) products. L-proline is used as stabilizer in the new Immune Globulin Intravenous (human) 10% product (Privigen®). The data were presented at the American Congress of Allergy, Asthma and Immunology (ACAAI) in Dallas, Texas.

> Read More
09 November 2007 New Hope in Immunodeficiency Treatment for Improved Tolerability and Convenience in the use of Immune Globulin Intravenous (Human) 10% Liquid (Privigen®)

CSL Behring today announced data on the use of L-proline as a new single stabilizer for Immune Globulin Intravenous (Human) 10% Liquid (Privigenâ). Researchers found that the use of L-proline, a naturally occurring amino-acid, inhibited dimer formation more efficiently when compared with other additives like glycine, used as a stabilizer in conventional immunoglobulin products. In addition, the formulation with L-proline was found to prevent aggregation. The data were presented today at the American Congress of Allergy, Asthma and Immunology (ACAAI) in Dallas, Texas.

> Read More
Page 51 of 52 First | Previous | Last

LinkedIn Twitter Facebook Google+